Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 201–300 of 1,000
d’Aquino, A. I., Maikawa, C. L., Nguyen, L. T., Lu, K., Hall, I. A., Jons, C. K., Kasse, C. M., Yan, J., Prossnitz, A. N., Chang, E., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101292 · Cited by 59
“62,63 In addition, semaglutide’s side-chain linker, which contains two carboxylic acid moieties, is significantly more hydrophilic than that of liraglutide’s, which contains only one carboxylic acid moiety.”
BackgroundSelf-citationSemaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Carlsson Petri, K. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0458-5 · Cited by 47
“This allows for subcutaneous injection once weekly [12].”
BackgroundDairy-derived peptides for satiety
Kondrashina, A. V., Brodkorb, A., & Giblin, L. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.103801 · Cited by 48
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
“It is similar to liraglutide in structure and has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26 so is stable against metabolic degradation [81].”
BackgroundSemaglutide seems to be more effective the other GLP-1Ras
Holst, J. J., & Madsbad, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.10 · Cited by 45
“This increased its half-life in humans to 165 hours without significantly changing its ability to activate the GLP-1 receptor (25,26).”
BackgroundRudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108931 · Cited by 46
Zhang, L., Li, C., Zhang, Z., Zhang, Z., Jin, Q., Li, L., & Hölscher, C. (2022) · Parkinson s Disease · doi:10.1155/2022/1428817 · Cited by 60
“It has an extended spacer for an attached C20 fatty acid for enhanced survival in the blood by binding to albumin [59].”
Klair, N., Patel, U. P., Saxena, A., Patel, D. N., Ayesha, I. E., Monson, N. R., & Ramphall, S. (2023) · Cureus · doi:10.7759/cureus.46197 · Cited by 66
“%) to native human GLP-1 [11].”
BackgroundBoshchenko, A. A., Маслов, Л. Н., Mukhomedzyanov, А. V., Zhuravleva, O. A., Сергеевна, С. А., Naryzhnaya, N. V., Zinoveva, A., & Ilinykh, P. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094900 · Cited by 47
“The plasma half-life of semaglutide (ozempic) is 46.1 h in mini-pigs after intravenous administration [78].”
BackgroundInfluentialEngineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320
Kjeldsen, T., Hubálek, F., Tagmose, T. M., Pridal, L., Refsgaard, H. H. F., Porsgaard, T., Gram-Nielsen, S., Hovgaard, L., Valore, H., Münzel, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01576 · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
Bækdal, T. A., Donsmark, M., Hartoft‐Nielsen, M., Søndergaard, F. L., & Connor, A. L. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.938 · Cited by 45
Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives
Ding, B., Zhu, Z., Guo, C., Li, J., Gan, Y., & Yu, M. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.019 · Cited by 46
“Since the rapid degradation of native GLP-1 in vivo , the longer-lasting GLP-1 analogs, such as Exenatide and Semaglutide, have been developed in clinical treatments 15,19,20 .”
BackgroundDarsalia, V., Klein, T., Nyström, T., & Patrone, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.022 · Cited by 43
Sass, M. R., Danielsen, A. A., Köhler‐Forsberg, O., Storgaard, H., Knop, F. K., Nielsen, M. Ø., Sjödin, A. M., Mors, O. N., Correll, C. U., Ekstrøm, C. T., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068652 · Cited by 46
Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature
Pavli, P., Triantafyllidou, O., Kapantais, E., Vlahos, N., & Valsamakis, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031909 · Cited by 44
“However, substitutions were made at positions 8 and 34 of GLP-1, where alanine and lysine were replaced by 2-aminoisobutyric acid and arginine, respectively [69].”
BackgroundCabrera, O., FICORILLI, J. V., Shaw, J., Echeverri, F., Schwede, F., Chepurny, O. G., Leech, C. A., & Holz, G. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101484 · Cited by 45
“Furthermore, their presence in islets may alter the potency and efficacy of glucagon or GLP-1[7-36]amide (GLP-1) when each is administered as a synthetic peptide.”
BackgroundGlycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide
Soudahome, A. G., Catan, A., Giraud, P., Kouao, S. A., Guérin-Dubourg, A., Debussche, X., Moullec, N. L., Bourdon, E., Bravo, S. B., Paradela‐Dobarro, B., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.815274 · Cited by 43
“Indeed, this strategy has been explored successfully by researchers from Novo Nordisk who recently developed a GLP-1 analogue called semaglutide (64).”
BackgroundOlesen, M. T. J., Walther, R., Poier, P. P., Dagnæs‐Hansen, F., & Zelikin, A. N. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201916124 · Cited by 41
Malik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41
“, 1992), semaglutide (Lau et al., 2015), dulaglutide (Glaesner et al.”
Alhindi, Y., & Avery, A. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100944 · Cited by 37
Albumin–Polymer–Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles
Autzen, A. A. A., Zuwała, K., Pilgram, O., Johansen, K. S., Tolstrup, M., Dagnæs‐Hansen, F., & Zelikin, A. N. (2016) · ACS Macro Letters · doi:10.1021/acsmacrolett.6b00544 · Cited by 41
Venanzi, M., Savioli, M., Cimino, R., Gatto, E., Palleschi, A., Ripani, G., Cicero, D. O., Placidi, E., Orvieto, F., & Bianchi, E. (2020) · Soft Matter · doi:10.1039/d0sm01011a · Cited by 40
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Sequence-based prediction of the intrinsic solubility of peptides containing non-natural amino acids
Oeller, M., Kang, R. J. D., Bolt, H. L., dos Santos, A. L. G., Weinmann, A. L., Nikitidis, A., Zlatoidský, P., Su, W., Czechtizky, W., Maria, L. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42940-w · Cited by 49
“Aminoisobutyric acid (AIB) is often used to make peptides more resistant against peptidases as it is not easily recognised 79 .”
Movahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 47
Bech, E. M., Martos-Maldonado, M. C., Wismann, P., Sørensen, K. K., van Witteloostuijn, S. B., Thygesen, M. B., Vrang, N., Jelsing, J., Pedersen, S. L., & Jensen, K. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00787 · Cited by 39
Staby, A., Steensgaard, D. B., Haselmann, K. F., Marino, J. S., Bartholdy, C., Videbæk, N., Schelde, O., Bosch‐Traberg, H., Spang, L. T., & Asgreen, D. J. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02817-9 · Cited by 41
“resulting in a half-life of approximately 7 days (16,17).”
BackgroundSelf-citationDalbøge, L. S., Christensen, M. S., Madsen, M. R., Secher, T., Endlich, N., Drenić, V., Manresa-Arraut, A., Hansen, H. H., Rune, I., Fink, L. N., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071661 · Cited by 43
“The long-acting GLP-1 analogue, semaglutide, which is currently approved for the treatment of T2D and obesity [11,12], has been demonstrated to improve cardiorenal outcomes in patients with T2D [9,10].”
BackgroundAlorfi, N. M., & Algarni, A. S. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s374741 · Cited by 53
Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386542 · Cited by 39
Hinds, C. E., Peace, E., Chen, S., Davies, I., Eid, L. E., Tomás, A., Tan, T., MINNION, J. S., Jones, B. J., & Bloom, S. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15288 · Cited by 42
“We note that this right shift is less marked than the HSA-induced shift in binding affinity noted during the development of semaglutide, 28 which is not surprising as the cAMP pathway is highly amplified.”
BackgroundOvergaard, R. V., Lindberg, S. Ø., & Thielke, D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13479 · Cited by 34
“Semaglutide has 94% amino acid sequence homology to native GLP-1,(8) with three structural modifications that prolong the half-life to approximately 1 week.(8,9) In two phase 3 trials, semaglutide was compared head-to-head with dulaglutide and exenatide extended release (ER) and was shown to be superior in reducing Hb…”
BackgroundDesign of Y2 Receptor Selective and Proteolytically Stable PYY3–36 Analogues
Østergaard, S., Kofoed, J., Paulsson, J. F., Madsen, K. G., Jorgensen, R., & Wulff, B. S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01046 · Cited by 36
Self-citationSeo, B., Park, M., & Song, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b19669 · Cited by 42
Andreassen, K. V., Larsen, A. T., Sonne, N., Mohamed, K. E., Karsdal, M. A., & Henriksen, K. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101282 · Cited by 39
“The characterization data demonstrated that the acylation worked as intended, improving the T(1)/2 and Tmax of KBP-066A to a similar range to semaglutide in rats, which has the same type of acylation [1,32].”
ResultSubstrate mediated enzyme prodrug therapy
Fejerskov, B., Olesen, M. T. J., & Zelikin, A. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.013 · Cited by 40
Fang, Z., Chen, S., Pickford, P., Broichhagen, J., Hodson, D. J., Corrêa, I. R., Kumar, S., Görlitz, F., Dunsby, C., French, P. M. W., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00022 · Cited by 38
Jensen, M., Sanni, S. J., Riber, D., Holst, J. J., ROSENKILDE, M. M., & Sparre‐Ulrich, A. H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102006 · Cited by 42
“These fi ndings align with previous results observed for semaglutide [29].”
ResultEffect of Lipidation on the Structure, Oligomerization, and Aggregation of Glucagon-like Peptide 1
Brichtová, E. P., Edu, I. A., Li, X., Becher, F. J., dos Santos, A. L. G., & Jackson, S. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00484 · Cited by 38
Méndez, M. M., Matter, H., Defoßa, E., Kurz, M. E., Lebreton, S., Li, Z., Lohmann, M., Löhn, M., Mors, H., Podeschwa, M. A. L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01071 · Cited by 38
Wright, E. E., & Aroda, V. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798127 · Cited by 47
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
Jung, H. N., & Jung, C. H. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22012 · Cited by 42
Patoulias, D., Popovic, D. S., Stoian, A. P., Janež, A., Sahebkar, A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108529 · Cited by 40
Mi, R., Cheng, H.-F., Chen, R., Bai, B., An, L., Gao, F., & Xue, G. (2024) · Brain Circulation · doi:10.4103/bc.bc_38_24 · Cited by 39
“[30] Weekly subcutaneous injections of semaglutide have been successful in treating diabetes.”
Cardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 34
Esposito, S., de Leonibus, M. L., Ingenito, R., Bianchi, E., Orsatti, L., & Monteagudo, E. S. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.07.009 · Cited by 37
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 43
Lucey, M., Ashik, T., Marzook, A., Wang, Y., Goulding, J., Oishi, A., Broichhagen, J., Hodson, D. J., Minnion, J., Elani, Y., et al. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.121.000270 · Cited by 38
Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264974 · Cited by 36
“A longer plasma half-life was secured by the attachment of a C18 fatty diacid, in line with the once-weekly GLP-1 receptor agonist semaglutide [21].”
BackgroundSelf-citationCardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling
Kooij, K. L., Koster, D. I., Eeltink, E., Luijendijk, M. C. M., Drost, L., Ducrocq, F., & Adan, R. A. H. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103925 · Cited by 40
“Semaglutide is optimized for a longer half-life in humans (160 vs. 12 h) and full dipeptidyl peptidase-4 stability (Lau et al., 2015).”
Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse
Peterson, R. G., Jackson, C. V., Zimmerman, K. M., Alsina‐Fernandez, J., Michael, M. D., Emmerson, P. J., & Coşkun, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179856 · Cited by 36
Solid‐Phase Thiol–Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist
Williams, E. T., Harris, P. W. R., Jamaluddin, A., Loomes, K. M., Hay, D. L., & Brimble, M. A. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805208 · Cited by 36
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Çaklılı, Ö. T., Cesur, M., Mikhailidis, D. P., & Rizzo, M. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392684 · Cited by 38
“Its half-life is 155–184 h.(38) The STEP (Semaglutide treatment effect in people) trial program assessed the effects of semaglutide on weight loss.”
BackgroundDirected Evolution Using Stabilized Bacterial Peptide Display
Navaratna, T. A., Atangcho, L., Mahajan, M. K., Vivekanandan, S., Case, M., Min, A., Tresnak, D. T., & Thurber, G. M. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10716 · Cited by 35
Trends in Therapeutic Conjugates: Bench to Clinic
Rudra, A., Li, J., Shakur, R., Bhagchandani, S. H., & Langer, R. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00828 · Cited by 37
The Design of a GLP‐1/PYY Dual Acting Agonist
Østergaard, S., Paulsson, J. F., Gerstenberg, M. K., & Wulff, B. S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202016464 · Cited by 38
Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01799-2 · Cited by 34
“Marketing of OW semaglutide has been granted in Europe since February 2018 and has been available for therapeutic use in Italy since September 2019 [15, 16].”
BackgroundSubcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk
Diab, H., Fuquay, T., Datta, P., Bickel, U., Thompson, J. E., & Krutsch, K. (2024) · Nutrients · doi:10.3390/nu16172886 · Cited by 41
“The drug has a binding affinity of 0.38 ± 0.06 nM for the GLP-1 receptor [10].”
BackgroundInfluentialRevisiting amino acids and peptides as anti-glycation agents
Chilukuri, H., Kulkarni, M. J., & Fernandes, M. (2018) · MedChemComm · doi:10.1039/c7md00514h · Cited by 39
Clinical potential of treatment with semaglutide in type 2 diabetes patients
Røder, M. E. (2019) · Drugs in Context · doi:10.7573/dic.212585 · Cited by 37
The emerging landscape of peptide-based inhibitors of PCSK9
Tombling, B. J., Zhang, Y., Huang, Y.-H., Craik, D. J., & Wang, C. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.903 · Cited by 34
Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries
Dergunova, L. V., Filippenkov, I. B., Limborska, S. A., & Myasoedov, N. F. (2023) · Genes · doi:10.3390/genes14050953 · Cited by 40
“Semaglutide (HXEGTFTSDVSSYLEGQAAK(C18diacid-γE-OEG-OEG)EFIAWLVRGRG), another long acting GL1-RA, has two amino acid substitutions compared to human GLP-1 (2-aminoisobutyric acid (Aib) 8, arginine (Arg) 34) and is derivatized at lysine 26 [84].”
BackgroundRaubenheimer, J., Myburgh, P. H., & Bhagavathula, A. S. (2024) · BMC Global and Public Health · doi:10.1186/s44263-024-00095-w · Cited by 42
Sharma, R., Wilkinson, L., Vrazic, H., Popoff, E., Lopes, S., Kanters, S., & Druyts, E. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1476332 · Cited by 29
Atangcho, L., Navaratna, T. A., & Thurber, G. M. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.008 · Cited by 38
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
“Semaglutide (Ozempic) 2016 GLP-1 analog with 94% sequence homology to human GLP-1; it resembles liraglutide with an additional Aib8 to prevent DPP-4–mediated cleavage and a C18-based fatty acid chain connected to Lys26 through a miniPEG space leading to a half-life of 160 hours (199) s.”
BackgroundAroda, V. R., Capehorn, M. S., Chaykin, L., Frias, J. P., Lausvig, N. L., Macura, S., Lüdemann, J., Madsbad, S., Rosenstock, J., Tabak, O., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13896 · Cited by 31
“…1); as add-on to existing stable background antidiabetes treatments (metformin, thiazolidinedione or both [SUSTAIN 2]; maximum two of metformin, thiazolidinedione and/or sul-phonylurea [SUSTAIN 3]; metformin ± sulphonylurea [SUSTAIN 4]); and as add-on to basal insulin ± metformin (SUSTAIN 5).”
BackgroundPatti, A. M., Giglio, R. V., Allotta, A., Bruno, A., Bella, T. D., Stoian, A. P., Ciaccio, M., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051362 · Cited by 36
“Semaglu-tide is a long-acting GLP-1RA with a 1-weekly extended release; it has been on the market in Europe since 2018 and is the only GLP-1RA currently available as both a subcutaneous and oral formulation [8,9].”
BackgroundMiller, B. S., Blair, J., Rasmussen, M. H., Maniatis, A. K., Mori, J., Böttcher, V., Kim, H.-S., Bang, R. B., Polak, M., & Horikawa, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad394 · Cited by 33
van Witteloostuijn, S. B., Mannerstedt, K., Wismann, P., Bech, E. M., Thygesen, M. B., Vrang, N., Jelsing, J., Jensen, K. J., & Pedersen, S. L. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00787 · Cited by 34
Nielsen, J. C. F., Hjørringgaard, C. U., Nygaard, M. M., Wester, A., Elster, L., Porsgaard, T., Mikkelsen, R. B., Rasmussen, S. A., Madsen, A. N., Schlein, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00417 · Cited by 34
Wang, Z.-J., Han, W.-N., Chai, S.-F., Li, Y., Fu, C.-J., Wang, C.-F., Cai, H.-Y., Li, X., Wang, X., Hölscher, C., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.022 · Cited by 36
Peptides in Cosmetics: From Pharmaceutical Breakthroughs to Skincare Innovations
Tang, Y., Nie, T., Zhang, L., Liu, X., & Deng, H. (2025) · Cosmetics · doi:10.3390/cosmetics12030107 · Cited by 35
“These modifications ensure prolonged therapeutic action, and semaglutide is currently undergoing phase III clinical trials [81].”
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 36
Hepatic Glucagon Receptor Signaling Controls Amino Acid Metabolism and Regulates Alpha Cell Mass
Elmelund, E., Galsgaard, K. D., Johansen, C. D., Trammell, S. A. J., Bomholt, A. B., Winther‐Sørensen, M., Hunt, J. E., Sørensen, C. M., Kruse, T., Lau, J. F., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105296 · Cited by 33
“, 1992) with transplanted glucagon-producing tumors and in glucagon-treated rabbits (Lazarus and Volk, 1958; Logothetopoulos and Salter, 1960; Logothetopoulos et al., 1960), is another example of the extensive biological consequences of increased glucagon receptor signaling.”
Self-citationNapoli, R., Berra, C., Catarig, A., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15020 · Cited by 32
“0 mg, has been approved by many regulatory agencies for treating adults with T2D, in addition to diet and exercise.(11,12) Compared with placebo and many active comparators, OW semaglutide showed superior, clinically relevant reductions in glycated haemoglobin (HbA1c) and body weight in the SUSTAIN clinical trials, wi…”
BackgroundSloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Nissan, N., Allen, M. C., Sabatino, D., & Biggar, K. K. (2024) · Biomolecules · doi:10.3390/biom14101303 · Cited by 36
“Despite the modern advances in peptide design, synthesis, and screening approaches, the development of peptide analogues often remains favoured over completely novel sequences [27,28], largely as a consequence of persisting cost discrepancies between the two approaches.”
BackgroundOral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
Pearson, S. M., Kietsiriroje, N., & Ajjan, R. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s229802 · Cited by 38
Liu, X., Zhang, N., Gu, X., Qin, Y., Song, D., Zhang, L., & Ma, S. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00134 · Cited by 31
pIChemiSt ─ Free Tool for the Calculation of Isoelectric Points of Modified Peptides
Frolov, A. I., Chankeshwara, S. V., Abdulkarim, Z., & Ghiandoni, G. M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01261 · Cited by 36
Kolar, G. R., Grote, S., & Yosten, G. L. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12528 · Cited by 32
Strategies to Optimize Peptide Stability and Prolong Half-Life
Shi, S. M., & Di, L. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-04544-8_4 · Cited by 31
Polex-Wolf, J., Deibler, K., Hogendorf, W. F. J., Bau, S. S., Glendorf, T., Stidsen, C. E., Tornøe, C. W., Dong, T., Lundh, S. H., Pyke, C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk4908 · Cited by 35
Self-citationCencioni, C., Malatesta, S., Benedetti, V. V., Licursi, V., Perfetto, L., Conte, F., Ranieri, D., Bartolazzi, A., Kunkl, M., Tuosto, L., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03263-w · Cited by 32
“Here, it has been demonstrated for the first time that SEMA, a GLP-1RA with known pharmacological effects on metabolic syndrome [43, 44], is able to reshape PDAC stroma preventing T lymphocyte exclusion by P4HA1-collagen-pCAF axis (Fig.”
On the causes of obesity and its treatment: The end of the beginning
Friedman, J. M. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.026 · Cited by 34
Ma, B., Fuhrmann, J., Henriksen, H. C., Khojasteh, S. C., Li, W., Liu, J., Plise, E. G., Yu, Q., & Cheruzel, L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02276 · Cited by 32
Li, Y., & Rosenblit, P. D. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1051-2 · Cited by 31
Yang, P., Zou, H., Amso, Z., Lee, C., Huang, D., Woods, A. K., Nguyen-Tran, V. T. B., Schultz, P. G., & Shen, W. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00093 · Cited by 33
Sorets, A. G., Rosch, J. C., Duvall, C. L., & Lippmann, E. S. (2020) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2020.08.009 · Cited by 32
Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor
Hennen, S., Kodra, J. T., Soroka, V., Krogh, B. O., Wu, X., Kaastrup, P., Ørskov, C., Rønn, S. G., Schluckebier, G., Barbateskovic, S., et al. (2016) · Scientific Reports · doi:10.1038/srep26236 · Cited by 33
Self-citationGomez-Peralta, F., & Abreu, C. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s165372 · Cited by 27
“Pharmacology and characteristics of the device The efficacy and safety demonstrated by liraglutide were the basis for the development of semaglutide.(13) After testing several molecules, in search of increasing their half-life to achieve a more convenient dosage, semaglutide was chosen.”
BackgroundTanaka, A., & Node, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0731-y · Cited by 32
“This may indicate that the effect of semaglutide on body weight reduction is relatively rapid-acting and dose-dependent, possibly resulting from the higher albumin affinity of semaglutide compared with liraglutide [18].”
BackgroundMallart, S., Ingenito, R., Bianchi, E., Bresciani, A., Esposito, S., Gallo, M., Magotti, P., Monteagudo, E., Orsatti, L., Roversi, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01533 · Cited by 29
Menzen, M., Berentzen, T. L., Catarig, A.-M., Pieperhoff, S., Simon, J., & Jacob, S. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2007-2061 · Cited by 29
Korsatko, S., Jensen, L., Brunner, M., Sach‐Friedl, S., Tarp, M. D., Holst, A. G., Heller, S. R., & Pieber, T. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13422 · Cited by 29
“The higher absolute concentrations of C-peptide, a marker of endogenous insulin production, observed with semaglutide vs placebo at each target PG level during the clamp were consistent with the ability of GLP-1RAs to stimulate insulin secretion in a glucose-dependent manner.(12,13,29) Importantly, C-peptide levels de…”
BackgroundResultInfluentialConjugation with glucagon like peptide-1 enables targeted protein degradation
Zhu, L., Zhou, Y., Zhang, B., Luo, Y., Chen, F., Yan, X., Cai, Y., Jiang, L., & Ge, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106908 · Cited by 31
Devices to overcome the buccal mucosal barrier to administer therapeutic peptides
Malhotra, S., Lijnse, T. M., O’Cearbhaill, E. D., & Brayden, D. J. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115572 · Cited by 33
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.